CDKN2A and hepatocellular carcinoma: In this study, we provide evidence that the simultaneous combination of the CDK4/6 inhibitors abemaciclib and ribociclib with lenvatinib is effective in Rb-proficient, p16INK4 negative HCC cells, producing synergistic anti-proliferative effects that persisted even after drug withdrawal.